Clinical Trial

Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The registration of this research plan was incorrect. A new registration has been done.
Summary
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-06-05
critical Reason stopped changed: — → The registration of this research plan was incorrect. A new registration has been done. 2026-06-05
notable Enrollment reduced: 43 -> 0 participants 2026-06-05
Trial Details
NCT Number NCT07532408
Lead Sponsor Peking Union Medical College Hospital
Conditions Aplastic Anemia
Start Date 2026-06
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-04